Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 7, 2012, Pages 951-958

  Jelčić, Ilijas ^a,b   Hsu, Katharine C ^c   Kakalacheva, Kristina ^d   Breiden, Petra ^a   Dupont, Bo ^c   Uhrberg, Markus ^e   Martin, Roland ^a,b   Münz, Christian ^d   Lünemann, Jan D ^d,f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

genes; multiple sclerosis; natural killer cell; T cell

Indexed keywords

HLA ANTIGEN CLASS 1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE DURATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PREVALENCE; RISK REDUCTION;

EID: 84863226325     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511431726     Document Type: Article

References (44)

1. Dyment DA, Ebers GC and Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104-110. (Pubitemid 38121313)
2. Oksenberg JR, Baranzini SE, Sawcer S and Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9: 516-526. (Pubitemid 351861542)
3. Jersild C, Fog T, Hansen GS, Thomsen M, Svejgaard A and Dupont B. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221-1225.
4. Fugger L, Friese MA and Bell JI. From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol 2009; 9: 408-417.
5. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274. (Pubitemid 40563170)
6. Moretta A, Marcenaro E, Parolini S, Ferlazzo G and Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008; 15: 226-233.
7. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997; 7: 753-763. (Pubitemid 28064889)
8. Yen JH, Moore BE, Nakajima T, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159-1167. (Pubitemid 32488368)
9. Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002; 169: 2818-2822. (Pubitemid 35013118)
10. Khakoo SI, Thio CL, Martin MP, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874. (Pubitemid 39038423)
11. Kulkarni S, Martin MP and Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin Immunol 2008; 20: 343-352.
12. Martinez-Rodriguez JE, Saez-Borderias A, Munteis E, Romo N and Roquer J, Lopez-Botet M. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy. Clin Immunol 2010; 137: 41-50.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846. (Pubitemid 41746873)
14. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
15. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ and Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169: 5118-5129. (Pubitemid 35217181)
16. Uhrberg M, Parham P and Wernet P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 2002; 54: 221-229. (Pubitemid 34824132)
17. Single RM, Martin MP, Meyer D, Gao X and Carrington M. Methods for assessing gene content diversity of KIR with examples from a global set of populations. Immunogenetics 2008; 60: 711-725.
18. Brant R. Power/Sample Size Calculator [Computer Software], 2005. Retrieved 15 September 2011, from http://www.meduniwien.ac.at/medstat/research/ samplesize/b2.html.
19. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005; 5: 201-214. (Pubitemid 40364822)
20. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31: 429-434. (Pubitemid 35154456)
21. Speiser DE, Valmori D, Rimoldi D, et al. CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999; 29: 1990-1999. (Pubitemid 29265555)
22. Huard B and Karlsson L. KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature 2000; 403: 325-328. (Pubitemid 30062390)
23. Huard B and Karlsson L. A subpopulation of CD8+ T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol 2000; 30: 1665-1675. (Pubitemid 30342809)
24. Karabon L, Jedynak A, Giebel S, et al. KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease. Tissue Antigens 2011; 78: 129-138.
25. Jennes W, Verheyden S, Demanet C, et al. Low CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands. PLoS One 2011; 6: e17043.
26. Winter CC, Gumperz JE, Parham P, Long EO and Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998; 161: 571-577. (Pubitemid 28323516)
27. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M and Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008; 180: 3969-3979.
28. Lorentzen AR, Karlsen TH, Olsson M, et al. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann Neurol 2009; 65: 658-666.
29. Jiao YL, Ma CY, Wang LC, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol 2008; 28: 343-349.
30. Jiao YL, Zhang BC, You L, et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol 2010; 30: 840-844.
31. Jones DC, Edgar RS, Ahmad T, et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immunity 2006; 7: 576-582. (Pubitemid 44614872)
32. Kimoto Y, Horiuchi T, Tsukamoto H, et al. Association of killer cell immunoglobulin-like receptor 2DL5 with systemic lupus erythematosus and accompanying infections. Rheumatology (Oxford) 2010; 49: 1346-1353.
33. Lowe DP, Cook MA, Bowman SJ and Briggs DC. Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology (Oxford) 2009; 48: 359-362.
34. Merino A, Malhotra R, Morton M, et al. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J Infect Dis 2011; 203: 487-495.
35. Momot T, Koch S, Hunzelmann N, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004; 50: 1561-1565. (Pubitemid 38608078)
36. Mousavi T, Poormoghim H, Moradi M, Tajik N, Shahsavar F and Asadifar B. Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylosing spondylitis. Iran J Immunol 2010; 7: 88-95.
37. Salim PH, Jobim M, Bredemeier M, et al. Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. Clin Exp Immunol 2010; 160: 325-330.
38. Santin I, Castellanos-Rubio A, Perez de Nanclares G, Vitoria JC, Castano L and Bilbao JR. Association of KIR2DL5B gene with celiac disease supports the susceptibility locus on 19q13.4. Genes Immunity 2007; 8: 171-176. (Pubitemid 46390917)
39. Suzuki Y, Hamamoto Y, Ogasawara Y, et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Invest Dermatol 2004; 122: 1133-1136. (Pubitemid 38651087)
40. Taniguchi M and Kawabata M. KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection. Immunogenetics 2009; 61: 717-730.
41. Yen JH, Moore BE, Nakajima T, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159-1167. (Pubitemid 32488368)
42. Zvyagin IV, Mamedov IZ, Britanova OV, et al. Contribution of functional KIR3DL1 to ankylosing spondylitis. Cell Mol Immunol 2010; 7: 471-476.
43. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.
44. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008; 131: 3118-3131.